To investigate the therapeutic efficacy and immune microenvironment remodeling realized through targeted SLC7A5 and anti-PD-1 agent combination therapy in vivo, we established 4T1 subcutaneous fat pat tumor models. The gene discussed is SLC7A5; the disease is neoplasm.